NRx Pharmaceuticals (NRXP) Wednesday said it received a first safety report for its investigational Covid-19 drug ZYESAMI from a Southwestern hospital.
The safety data showed that 16 out of 19 (84%) patients with COVID-19 respiratory failure, who were treated with ZYESAMI by Dec 31, 2021 have survived, and no Serious Adverse Events (SAEs) were reported.
The patients were treated under the Federal Right to Try Law.
These data were included the Emergency Use Authorization application to the FDA for the treatment of patients with critical COVID-19, NRx said.
NIH-sponsored Phase 3 ACTIV-3b (TESICO) study of ZYESAMI is currently going on.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.